(19)
(11) EP 1 772 142 A3

(12) EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
14.09.2011 Bulletin 2011/37

(43) Date of publication A2:
11.04.2007 Bulletin 2007/15

(21) Application number: 07100048.3

(22) Date of filing: 03.12.2001
(51) International Patent Classification (IPC): 
A61K 31/575(2006.01)
 A61P 11/00(2006.01)
(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
Designated Extension States:
RO SI

(30) Priority: 04.12.2000 GB 0029562

(62) Application number of the earlier application in accordance with Art. 76 EPC:
01999366.6 / 1341542

(71) Applicants:
  • Novartis AG
    4056 Basel (CH)

    BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR 
  • Novartis Pharma GmbH
    1230 Wien (AT)

    AT 

(72) Inventors:
  • Cuenoud, Bernard
    1006, Lausanne (CH)
  • Fairhurst, Robin Alec
    Horsham, West Sussex RH12 5AB (GB)
  • Lowther, Nicholas
    Horsham, West Sussex RH13 7HT (GB)

(74) Representative: McLean, Craig Sutherland et al
Novartis AG Corporate Intellectual Property
4002 Basel
4002 Basel (CH)

   


(54) Organic compounds


(57) A medicament comprising, separately or together, (A) a compound of formula

in free or pharmaceutically acceptable salt or solvate form and (B) a corticosteroid, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease, the molar ratio of (A) to (B) being from 100:1 to 1:300.





Search report